Therapeutic discovery platform

Traditional drug discovery is slow, expensive, and carries high attrition in clinical development. For rare diseases, the economics are especially difficult — small patient populations make conventional approaches commercially unviable, leaving many conditions without therapeutic options despite known biological mechanisms.

The platform combines high-throughput molecular screening with machine learning models trained on curated datasets from Nordic biobanks. By computationally prioritising drug-target hypotheses before wet-lab validation, the team shortens the path from target identification toward development milestones. The architecture allows systematic pursuit of multiple indications in parallel.

A lead programme has advanced into preclinical validation for a rare metabolic disorder, with additional targets under active evaluation. Early partnership discussions reflect how platform depth can attract collaborators without forcing a single-asset story.